KR20120004286A - Pellino 1 as a marker for the diagnosis or prognosis of lymphoma - Google Patents

Abstract

PURPOSE: A biomarker which is specific to lymphatic tumor is provided to accurately and easily diagnose lymphatic tumor and to study lymphoma formation. CONSTITUTION: A composition for diagnosis or prognosis of lymphatic tumor contains an agent for measuring mRNA or protein level of Pellino 1(Genbank ID : 57162). The agent includes an antisense oligonucleotide, primer pair, probe, or antibody which is specific to Pellino 1 gene or protein. A method for providing information for diagnosing or predicting prognosis of lymphatic tumor comprises: a step of measuring mRNA level from a biological sample of a patient with possibility of lymphatic tumor using the primer; and a step of comparing mRNA level with a control group. The sample includes whole blood, serum, plasma, urine, lymphoid, or cells.

Description

Pellino 1 as a marker for the diagnosis or prognosis of lymphoma}

The present invention relates to a biomarker specific for lymphoma, and more particularly, a kit comprising a composition for diagnosing or prognostic lymphoma, including a biomarker, Pellino 1 gene mRNA or an agent measuring a protein level thereof, the marker The present invention relates to a method for providing information for the diagnosis or prognosis of lymphoma used, and a method for screening a lymphoma therapeutic agent using the marker.

Lymphoma refers to malignant lymphoma of cells (lymphocytes and histocytes) belonging to lymphoid tissues and can be briefly classified into Hodgkin's disease and non-Hodgkin's lymphoma. In Korea, non-Hodgkin's lymphomas make up the vast majority. More than 95% of non-Hodgkin's lymphomas are mostly malignant lymphomas, and Hodgkin's lymphoma is only about 5% of malignant lymphomas. Occupies%

Non-Hodgkin lymphomas are lymphomas of the immune system, originating from T cells, B cells, or histocytes, but most of the non-Hodgkin lymphomas (80-90%) are of B cell origin and the rest are T or NK cell origins. It is known to be very rare. Among non-Hodgkin lymphomas, diffuse large B cell lymphoma (4-5 times larger than small lymphocytes, mixed with cells with cracks in the nucleus and without cells) is the most common type. Accounted for 40%.

The general diagnosis of lymphocytic lymphoma is performed by hematoxylin-eosin staining, flow cytometry, immunohistochemistry, Giemsa staining, cytogenetic examination, etc. for histochemical examination. Immunohistochemical tests for lymphomas distinguish B- or T-cell immunophenotypes (e.g., CD5, CD10, CD19, CD20, etc.), and cytogenetic tests for chromosomal tests or BCL- 2, c-Myc, ALK-1, BCL-6, MALT1-API2 and the like is known to analyze the translocation (translocation).

However, most of the above assays are not selective and specific for specific lymphocytic lymphomas, and efficient assays targeting specific genes for diagnosis are reported to be in the research stage.

For example, diagnosis and treatment targeting specific genes, such as in chronic myelogenous leukemia (CML), which account for 15-20% of all leukemias, is the ideal and only approach. CML is related to the Philadelphia chromosome, which is the antagonistic of BCR gene on chromosome 9 and ABL gene on chromosome 22, resulting in a new fusion protein with tyrosine kinase activity called BCR-ABL. Will be. Gleevec, a selective anticancer drug for CML, is an anticancer compound that inhibits the growth and cleavage of CML by targeting BCR-ABL fusion protein and blocking kinase activity.

Serine / threonine kinase, BubR1 (BUB1B), is well known as a key checkpoint protein in the cell cycle that regulates / controls mitosis, and the present inventors have identified and reported the function of BubR1 as a novel lymphoma suppressor protein. I've done it. In addition, many overseas research groups are deadly diseases of humans such as cancer development, aging, and genetic diseases caused by abnormal regulation of BubR1 protein, inactivation by factors other than genetic or genetic, or lack of function. Has been reported. In addition, the inventors have discovered a new binding protein of BubR1 using a research technique called 'yeast-two hybrid', and the discovered protein is Pellino 1 (or Peli 1). The exact in vivo function of the Pellino 1 gene is little known, and only two other researchers recently reported that it was involved in the production of inflammatory cytokines.

As such, in the background of the need for selective and specific diagnostic methods for specific lymphocytic lymphomas targeting specific genes, the present inventors have made diligent efforts to find such genetic markers. In addition, we found that the frequency of expression increased significantly, and Pellino 1 was analyzed in patients with B-cell lymphoma expressing Pellino 1 and B-cell lymphoma without Pellino 1. The cumulative survival rate of B-cell lymphoma patients expressing PSA decreased by about 40%. Accordingly, the present inventors have completed the present invention by confirming that the Pellino 1 protein can be used as a marker for judging the prognosis of lymphoma patients in addition to its efficacy as a diagnostic marker of lymphoma.

One object of the present invention relates to a composition for diagnosing or prognostic lymphoma, comprising a Pellino 1 (Genbank ID: 57162) gene mRNA or an agent measuring the protein level thereof.

Another object of the present invention relates to a kit for diagnosing or prognostic lymphoma comprising the composition.

Another object of the present invention is to measure mRNA from a biological sample of suspected lymphoma using primers that specifically bind to the Pellino 1 gene; And comparing the increase of the mRNA level with the mRNA level of a normal control sample.

Another object of the present invention is to contact an antibody specific for a Pellino 1 protein with a biological sample of a suspected lymphoma and confirm the protein level by antigen-antibody complex formation; And it relates to a method of providing information for the diagnosis or prognosis of lymphoma comprising comparing the increase in the amount of protein formation with the protein level of the normal control sample.

Yet another object of the present invention is to provide a method for treating lymphoma, comprising: a) treating a lymphoma cell with a candidate for treating lymphoma; (b) measuring the expression level of the pellino 1 gene or the expression level of the protein encoded by the candidate substance-treated cells; And (c) comparing the expression level of the pellino 1 gene or the expression level of the protein encoded by the gene with a control.

As one aspect for achieving the above object, the present invention relates to a composition for diagnosing or predicting lymphoma, comprising an agent for measuring the Pellino 1 (Genbank ID: 57162) gene mRNA or protein level thereof.

The term "diagnosis" in the present invention means identifying the presence or characteristic of a pathological condition. For the purposes of the present invention, it is to confirm the development of lymphoma. As used herein, the term "prognosis" refers to determining whether such subjects relapse, metastasis, drug reactivity, resistance, etc. after treatment of lymphoma. Preferably, when using the anti-Pellino 1 antibody of the present invention, by checking the expression level of Pellino 1 from the sample of the individual, whether the subject has a good prognosis for the future 60 months or more, as well as whether the lymphoma of the individual Up to predictable.

As used herein, the term "marker for predicting diagnosis or prognosis, a marker for predicting diagnosis or prognosis" refers to a substance capable of diagnosing lymphoma cells from normal cells, and shows an increase in patients with lymphomas compared to normal cells. Organic biomolecules such as visible polypeptides or nucleic acids (eg mRNA), lipids, glycolipids, glycoproteins, sugars (monosaccharides, disaccharides, oligosaccharides, etc.). For the purposes of the present invention, a marker for diagnosing or prognostic lymphoma is Pellino 1, a gene with increased expression in lymphoma.

In the present invention, the term "Pellino 1" is a gene encoding a protein that binds to BubR1, a serine / threonine kinase, which is not well known for its functions in vivo. It was first identified. The sequence of Pellino 1 can be freely obtained by those skilled in the art from a known genetic database. Preferably it may be Gene ID 57162 of NCBI GenBank.

As used herein, the term "lymphoma" refers to lymph cell proliferative diseases originating from immune cells, such as B-lymphocytes, T-lymphocytes, natural killer cells, lymphocytes, or histocytes, but are not limited thereto. Non-Hodgkin's lymphoma or B-cell lymphoma.

According to one embodiment of the present invention, it was confirmed that the expression of Pellino 1 was specifically increased in B-cell lymphoma (Table 1), and the survival rate was reduced by 40% in patients with positive Pellino 1 expression (FIG. 3). . In addition, as a result of comparing the mRNA levels of Pellino 1 in each tissue of the mouse, it was confirmed that the expression of Pellino 1 is high in tissues with many immune cells, such as organs, lymph nodes, thymus (Fig. 4). This suggests that Pellino 1 can be used as a marker for the diagnosis or prognosis of the lymphoma from immune cells.

In the present invention, the term "mRNA expression level measurement" is a process of confirming the presence of mRNA and the expression level of the marker gene in a biological sample for diagnosing or predicting lymphoma, can be known by measuring the amount of mRNA. For this, RT-PCR, competitive RT-PCR, Real-time RT-PCR, RNase protection assay (RPA), northern blotting (northern) blotting), or DNA microarray chips, but are not limited thereto. Specifically, the agent for measuring the mRNA level of the gene in the present invention is preferably an antisense oligonucleotide, primer pair or probe, since the nucleic acid sequence of the Pellino 1 genes used as markers of the lymphoma has been found registered in the gene bank One skilled in the art can design primers or probes that specifically amplify specific regions of these genes based on the sequences.

As used herein, the term “antisense” refers to a nucleotide base in which an antisense oligomer hybridizes with a target sequence in RNA by Watson-Crick base pairing, allowing formation of mRNA and RNA: oligomeric heterodimers, typically within the target sequence. Refers to oligomers having a sequence of and a backbone between subunits. The oligomer may have exact sequence complementarity or approximate complementarity to the target sequence. These antisense oligomers can alter or process the processing of mRNA, which blocks or inhibits translation of mRNA and produces splice variants of the mRNA.

As used herein, the term "primer" refers to a nucleic acid sequence having a short free 3'hydroxyl group, which can form complementary templates and base pairs and is a starting point for copying the template. It refers to a short nucleic acid sequence that functions as. Primers can initiate DNA synthesis in the presence of four different nucleoside triphosphates and reagents for polymerization (ie, DNA polymerase or reverse transcriptase) at appropriate buffers and temperatures. In the present invention, PCR amplification is performed using the sense and antisense primers of the marker polynucleotide of the present invention to diagnose lymphoma or predict the prognosis through the generation of a desired product. PCR conditions, sense and antisense primer lengths can be modified based on what is known in the art.

As used herein, the term "probe" refers to a nucleic acid fragment such as RNA or DNA, which is short to several bases to hundreds of bases, which is capable of specific binding with mRNA. You can check the presence. Probes may be made in the form of oligonucleotide probes, single stranded DNA probes, double stranded DNA probes, RNA probes, and the like. In the present invention, hybridization may be performed using a probe complementary to the marker polynucleotide of the present invention, thereby predicting the diagnosis or prognosis of lymphoma through hybridization. The selection and hybridization conditions of the appropriate probe are based on those known in the art. Can be transformed into

Antisense oligonucleotides, primers or probes of the present invention can be chemically synthesized using the phosphor amidite solid support method, or other well known methods. Such nucleic acid sequences may also be modified using many means known in the art. Non-limiting examples of such modifications include methylation, capping, substitution with one or more homologs of natural nucleotides, and modifications between nucleotides, eg, uncharged linkages such as methyl phosphonate, phosphoester, phosphoro Amidates, carbamates, etc.) or charged linkages (eg, phosphorothioates, phosphorodithioates, etc.).

In the present invention, the term "agent for measuring the expression level of a protein" is a process of confirming the presence and expression level of a protein expressed in a marker gene in a biological sample for the diagnosis or prognosis of lymphoma. The amount of the protein is determined using an antibody that binds specifically to the antibody. Western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay, radioimmunodiffusion, Ouchterlony immunodiffusion, and rockets Immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, protein chip, and the like, but are not limited thereto.

As used herein, the term "antibody" refers to a specific protein molecule directed to an antigenic site as it is known in the art. For the purposes of the present invention, an antibody means an antibody that specifically binds to a marker of the present invention, which antibody is cloned into an expression vector according to a conventional method to obtain a protein encoded by the marker gene. From the obtained protein, it can be prepared by a conventional method. Also included are partial peptides that may be made from such proteins, and the partial peptides of the present invention include at least seven amino acids, preferably nine amino acids, more preferably twelve or more amino acids. The form of the antibody of the present invention is not particularly limited and a part thereof is included in the antibody of the present invention and all immunoglobulin antibodies are included as long as they are polyclonal antibody, monoclonal antibody or antigen-binding. Furthermore, the antibodies of the present invention also include special antibodies such as humanized antibodies. Antibodies used in the present invention include functional fragments of antibody molecules as well as complete forms having two full length light chains and two full length heavy chains. The functional fragment of an antibody molecule means the fragment which has at least antigen binding function, and includes Fab, F (ab '), F (ab') 2, and Fv.

Preferably, in the present invention, when 5% or more of tissues are stained by Pellino 1 antibody in immunohistochemical staining of patients with diffuse large-cell B-cell lymphoma using Pellino 1 antibody, the diseased subject is determined to be a diseased individual (FIG. 2). , As the expression of the Pellino 1 protein increases, it was confirmed that the survival rate of the affected individuals decreased by about 40% (FIG. 3).

As another aspect, the present invention relates to a kit for diagnosing or prognostic lymphoma comprising the above composition.

The lymphoma may comprise a disease of the kind described above.

Kit of the present invention can detect and detect the mRNA expression level of the Pellino 1 gene corresponding to the marker protein or the expression level of the protein can be diagnosed and predicted lymphoma. The kit for detecting markers of the present invention may include primer probes for lymphoma diagnosis and prognosis prediction, or antibodies that selectively recognize markers, as well as one or more other component compositions, solutions, or devices suitable for analytical methods.

As a specific example, the kit for measuring the mRNA expression level of the marker genes in the present invention may be a kit containing the necessary elements necessary to perform RT-PCR. RT-PCR kits include test tubes or other appropriate containers, reaction buffers, deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNase inhibitors, DEPC, as well as individual primer pairs specific for the marker gene. -May include DEPC-water, sterile water, and the like.

In addition, the kit of the present invention may be a kit for detecting a diagnostic marker including an essential element necessary for performing a microarray chip. The microarray chip kit may include a substrate to which a cDNA corresponding to a gene or a fragment thereof is attached with a probe, and the substrate may include a cDNA corresponding to a quantitative control gene or a fragment thereof, using a marker of the present invention. It can be manufactured easily by the manufacturing method commonly used in the industry. In order to fabricate a microarray chip, a micropipetting method or a pin type using a piezoelectric method for immobilizing the searched marker as a probe DNA molecule on a substrate of a DNA chip. It is preferable to use a method using a spotter such as but not limited thereto. The substrate of the microarray chip is preferably coated with an active group selected from the group consisting of amino-silane, poly-L-lysine, and aldehyde, but is not limited thereto. . In addition, the substrate is preferably selected from the group consisting of slide glass, plastic, metal, silicon, nylon membrane and nitrocellulose membrane, but is not limited thereto.

In addition, the kit for measuring the protein expression level expressed by the coding of the marker genes in the present invention is a secondary antibody labeled with a substrate, a suitable buffer, a coloring enzyme or a fluorophore for the immunological detection of the antibody, and color development Substrates and the like. The substrate may be a nitrocellulose membrane, a 96 well plate synthesized with a polyvinyl resin, a 96 well plate synthesized with a polystyrene resin, a slide glass made of glass, and the like. The chromophore may be a peroxidase or an alkaline force. Fatty acid (alkaline phosphatase) and the like can be used, the fluorescent material may be used FITC, RITC, etc., the color substrate is ABTS (2,2'-azino-bis- (3-ethylbenzothiazoline-6-sulfur Phonic acid)) or OPD (o-phenylenediamine), TMB (tetramethyl benzidine) can be used.

In another aspect, the present invention provides a method for treating mRNA of a lymphoma suspected patient using a primer that specifically binds to the Pellino 1 gene; And comparing the increase of the mRNA level with the mRNA level of a normal control sample.

More specifically, expression of the gene can be detected at the mRNA level or at the protein level, and the separation of mRNA or protein from the biological sample can be performed using known processes.

Analytical methods for measuring mRNA levels include, but are not limited to, reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, northern blotting, DNA microarray chip, and the like. . Through the above detection methods, it is possible to compare the amount of mRNA expression in normal control subjects and suspected lymphomas, and to determine whether or not the significant amount of expression in the marker gene is increased or not. You can check it. mRNA expression level measurement is preferably by using a reverse transcriptase polymerase reaction method or a DNA microarray chip using a primer specific for the gene used as a marker. The reverse transcriptase polymerase reaction is electrophoresis after the reaction to confirm the band pattern and the thickness of the band to determine the mRNA expression and degree of the marker gene used for the diagnosis and prognosis of lymphoma by comparing with the normal control, Lymphoma diagnosis and prognosis can be simplified.

On the other hand, the DNA microarray chip uses a DNA chip in which the nucleic acid corresponding to the marker gene or a fragment thereof is attached to a glass-like substrate at a high density. cDNA probes can be prepared, hybridized to DNA chips and then predicted for diagnosis and prognosis of lymphoma. More specifically, it may be performed by including the following steps; Isolating mRNA of a marker gene specifically expressed in lymphoma from a sample of the individual; Labeling the mRNAs isolated from the sample of the individual and the mRNA of the normal control group with different fluorescent substances while synthesizing them with cDNA; Hybridizing the cDNAs labeled with the different fluorescent materials with a DNA microarray chip; And separating the hybridized DNA microarray chip to compare the mRNA expression level of the marker gene disclosed in the present invention with the mRNA expression level of the corresponding gene in the sample of the normal control. The fluorescent material is preferably selected from the group consisting of Cy3, Cy5, poly L-lysinefluorescein isothiocyanate (FITC), rhodamine-B-isothiocyanate (RITC), and rhodamine (rhodamine), but is not limited thereto. All materials can be used. In addition, the DNA microarray chip may use 36 k Human V4.0 OpArray oligo microarray (Operon, Germany) or Whole human genome oligo microarray (Agilent, USA) and the like, but is not limited thereto. As long as the DNA chip is loaded with an over or low expression gene.

In another aspect, the present invention provides a method for preparing protein, comprising the steps of contacting an antibody specific for Pellino 1 protein with a biological sample of a suspected lymphoma to confirm protein levels by antigen-antibody complex formation; And it relates to a method of providing information for the diagnosis or prognosis of lymphoma comprising comparing the increase in the amount of protein formation with the protein level of the normal control sample.

As used herein, the term "sample of an individual" includes, but is not limited to, tissues, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid or urine, and the like, which differ in the expression level of the marker gene.

Preferably, the disease for diagnosis or prognosis prediction in the method of providing information for diagnosis or prognosis prediction may be Hodgkin's lymphoma, non-Hodgkin's lymphoma, or B cell lymphoma as described above.

Analytical methods for measuring protein levels include Western blot, ELISA, radioimmunoassay, radioimmunoassay, oukteroni immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, Protein chips and the like, but is not limited thereto. Through the above analysis method, it is possible to compare the amount of antigen-antibody complex formation in suspicious lymphoma, and to determine whether the expression level of the marker gene is increased in protein, and to diagnose the actual lymphoma in suspicious lymphoma. Can be.

As used herein, the term “antigen-antibody complex” means a combination of a marker protein and an antibody specific thereto, and the amount of antigen-antibody complex formed can be measured quantitatively through the size of a signal of a detection label. Do.

The protein expression level can be measured by ELISA. ELISA is a direct ELISA using a labeled antibody that recognizes an antigen attached to a solid support, an indirect ELISA using a labeled antibody that recognizes a capture antibody in a complex of antibodies that recognize an antigen attached to a solid support, attached to a solid support Direct sandwich ELISA using another labeled antibody that recognizes the antigen in the antibody-antigen complex, a labeled antibody that recognizes the antibody after reacting with another antibody that recognizes the antigen in the complex of the antigen with the antibody attached to the solid support Various ELISA methods include indirect sandwich ELISA using secondary antibodies. For example, by attaching an antibody to a solid support and reacting a sample, a labeled antibody that recognizes the antigen of the antigen-antibody complex is enzymatically developed or labeled for an antibody that recognizes the antigen of the antigen-antibody complex. It can be detected by the sandwich ELISA method which attaches the secondary antibody thus enzymatically and colors it. The degree of complexation of the marker protein with the antibody can be confirmed to predict the diagnosis or prognosis of the lymphoma.

In addition, Western blot using one or more antibodies to the marker can be used. The whole protein is isolated from the sample, electrophoresed to separate the protein according to size, and then transferred to the nitrocellulose membrane to react with the antibody. The amount of the generated antigen-antibody complex can be confirmed by using a labeled antibody to confirm the amount of the protein produced by the expression of the gene, and the diagnosis and prognosis of the lymphoma can be made. The detection method comprises a method of examining the expression level of the marker protein in the normal control group and the expression level of the marker protein in the suspected lymphoma. Protein levels can be expressed as absolute (eg μg / ml) or relative (eg relative intensity of signals) differences of the marker proteins described above. In addition, immunohistostaining with one or more antibodies to the marker can be performed. After collecting and immobilizing the tissue of the suspected lymphoma, paraffin embedding blocks are prepared by methods well known in the art. These are cut into slices of several μm thickness, adhered to glass slides, and reacted with a selected one of the above antibodies by a known method. The unreacted antibody is then washed and labeled with one of the above-mentioned detection labels to read whether or not the antibody is labeled on a microscope.

In addition, a protein chip in which one or more antibodies against the marker are arranged at a predetermined position on the substrate and immobilized at high density may be used. In the method of analyzing a sample using a protein chip, the protein is separated from the sample, and the separated protein is hybridized with the protein chip to form an antigen-antibody complex, and then read, to confirm the presence or expression of the protein, Lymphoma diagnosis and prognosis predictions can be confirmed.

In another aspect, the present invention provides a method for treating lymphoma, comprising: (a) treating a lymphoma cell with a candidate substance for treating lymphoma; (b) measuring the expression level of the pellino 1 gene or the expression level of the protein encoded by the candidate substance-treated cells; And (c) comparing the expression level of the pellino 1 gene or the expression level of the protein encoded by the gene with a control.

The lymphoma may be, but is not limited to, Hodgkin's lymphoma and non-Hodgkin's lymphoma.

As used herein, the term "control" refers to a normal subject who does not have lymphoma.

Specifically, it can be usefully used for screening lymphoma therapeutics by a method that compares the increase or decrease in the expression of Pellino 1 in the presence and absence of a candidate for treating lymphoma. Substances that indirectly or directly reduce the concentration of Pellino 1 can be selected as therapeutic agents for the lymphomas disclosed herein. That is, by specifying the expression level of the marker Pellino 1 of the present invention in the lymphoma cells disclosed herein in the absence of a lymphoma treatment candidate, and also specifying the expression level of the marker Pellino 1 of the present invention in the presence of the lymphoma treatment candidate After comparing the two, a substance whose expression level of the marker of the present invention in the presence of a candidate for treating lymphoma is lower than the expression level of the marker in the absence of the candidate for treating lymphoma can be predicted as a therapeutic agent for the lymphoma disclosed herein. .

The therapeutic agent includes a substance capable of inhibiting the expression of Pellino 1 without limitation, and examples thereof may be a compound, siRNA, antisense oligonucleotide, antibody, and the like. According to one embodiment of the present invention, it was confirmed that the expression of Pellino 1 is high in patients with B cell lymphoma or in poor survival prognosis, and thus it can be used as a target of therapeutic agents (FIGS. 2 and 3).

The present invention has an effect that can be used as an indicator of the data useful for the treatment and prognosis of the lymphoma by discovering and providing a diagnostic marker that can determine the diagnosis and prognosis of the lymphoma. In addition, using the marker Pellino 1 of the lymphoma according to the present invention can accurately and easily determine the incidence of the lymphoma, can be used as a specific target in the study of the development of therapeutic agents for lymphoma, and furthermore can be used for the study of lymphoma formation. Can be.

FIG. 1 is a photograph of a probe of a centromere gene, which is a control group of Pellino 1, and a fluorescent in situ fusion method (FISH) to confirm the location on the chromosomes of Pellino 1 in five cell lines.
Figure 2 is a photograph showing the immunohistochemical staining results for Pellino 1 in the tissues of patients with diffuse large cell type B lymphoma.
3 is a graph analyzing the prognosis of patients with diffuse large cell type B lymphoma according to Pellino 1 expression.
Figure 4 is a graph comparing the expression of Pellino 1 mRNA in each tissue and cells of the mouse.

Hereinafter, the present invention will be described in more detail with reference to the following examples. These embodiments are only for illustrating the present invention, and the scope of the present invention is not construed as being limited by these embodiments.

Example  One: Weston Blotting  through Pellino  Protein expression comparison analysis of 1

Western blotting was performed to compare the expression of Pellino 1 protein in five normal cell lines and various cancer cell lines. Various cultured cells were lysed using lysis buffer (20mM HEPES pH7.6, 250mM NaCl, 1.5mM MgCl ₂ , 20% glycerol, 0.1% triton X-100, 1mM DTT, 1mM PMSF, protease inhibitor cocktail) And centrifuged to obtain a cell extract of the supernatant and quantified. 250 µg cell extracts were subjected to electrophoresis on 8% SDS-PAGE, and then transferred to nitrocell µose membrane, and then the membrane was TBS-T buffer solution containing 5% skim milk (100 mM NaCl, 20 mM Tris-HCl pH7. 4, 0.05% Tween 20) was blocked at room temperature for 1 hour. The antibody against Pellino 1 was diluted 1: 1500 in TBS-T buffer solution containing 3% BSA, reacted at 4 ° C. for 12 hours or more, and washed three times for 10 minutes in TBS-T buffer solution. The secondary antibody to which HRP (horseradish peroxidase) was attached was diluted 1: 3000 in a blocking solution, reacted at room temperature for 2 hours, and washed three times for 10 minutes in TBS-T buffer. Peroxidase was activated and developed by using ECL solution, and then exposed to X-ray film. The relative Pellino 1 protein expression levels are compared in Table 1 below.

Western blotting allows 25-50 μg cell extracts to identify / identify most protein expressions, but Pellino 1 does not recognize expression in many cell lines even at 250 μg cell extracts. Could not. However, when Pellino 1 was overexpressed and the vector was introduced into a (2 μg / 60 mm-dish) cell line, expression identification of the Pellino 1 gene introduced in about 10 μg of the cell extract was easily confirmed with the same antibody. However, intracellular Pellino 1 protein was able to discern expression in B cell lymphoma cell lines and showed relatively high levels of expression (Table 1).

In other words, it was found that Pellino 1 protein is specifically expressed in B cell lymphoma.

Example  2: Semiquantity  Polymerase chain reaction Semi - quantitive RT - PCR Of Pellino 1) mRNA  Expression comparison analysis

RNA was extracted from five normal and various cancer cell lines, respectively. After RNA was extracted using RNAeasy prep KIT (Qiagen), 1.2 μg RNA was taken and cDNA was synthesized using cDNA synthesis kit (promega). Primers used for RT-PCR are as follows.

<Pellino 1>

Forward primer: TGTAGTAACTGACACGGTTCCT (SEQ ID NO: 1)

Reverse primer: TCCATCTGATGTCTTCCATTTGG (SEQ ID NO: 2)

<GAPDH>

Forward primer: GGCATGGACTGTGGTCATGAG (SEQ ID NO: 3)

Reverse primer: TGCACCACCAACTGCTTAGC (SEQ ID NO: 4)

28 semi-quantitative polymerase chain reactions were carried out using cDNA as a template, using the primers for 30 seconds at 94 ° C, 1 minute at 60 ° C, and 1 minute 30 seconds at 72 ° C. 10 μl of the PCR reaction product was taken and electrophoresed on a 12% agarose gel in the presence of ethidium bromide to compare the bands.

The results were quantified and shown in Table 1 above. As with protein expression, Pellino 1 mRNA expression was also relatively high in B-cell lymphoma cell lines. Unlike comparison of protein expression levels, Pellino 1 mRNA expression was confirmed in almost all cell lines. However, compared with many other genes, mRNA expression of Pellino 1 was also significantly lower (Table 1).

Example  3: fluorescence in situ Fluorescence in situ hybridization ; FISH ) On chromosomes Pellino  1 position check

In order to perform Fluorescence in situ hybridization (FISH), first, colcemid was added to each of L132, HeLa, amniocytes, adipose-derived stem cells, and Ramos, and cultured for 1 hour. It was. After the culture solution was removed, the solution was preheated to 37 ° C (hypotonic solution) (0.8% sodium citrate) and allowed to stand for 20 minutes. After removing the cells and centrifugation, the supernatant was removed and the solution was fixed and centrifuged for 10 minutes. Thereafter, the supernatant was removed and the fixed solution was further treated and left at 4 ° C for at least 30 minutes. After centrifugation for 10 minutes, the supernatant was removed, the fixed solution was treated and centrifuged twice for 10 minutes. After the supernatant was removed, 0.5 ml of the fixed solution was added and dropped to 25 µl on a slide, and dried in a slide drier overnight. The slide, which was about one week at room temperature, was allowed to stand for 30 minutes in 2XSSC at 37 ° C., and then dried for 2 minutes in 70%, 85%, and 100% ethanol. Drop 10 μl of Pellino 1 or allotopic probe and cover the cover glass. After sealing with a rubber adhesive along the cover glass edge, it was left at 75 ° C for 5 minutes. After hybridization overnight at 37 ° C., the cover glass was removed and allowed to stand at 45 ° C. 50% formamide / 2XSSC (neutral) for 10 minutes. After this was repeated two more times, it was allowed to stand at 45 ° C. 2XSSC for 5 minutes and then at 45 ° C. 4XSSC / 0.1% tween20 for 15 minutes. After standing in 70%, 85%, and 100% ethanol for 1 minute, dried, 10 μl of DAPI was dropped, the cover glass was covered, and dried and observed with a fluorescence microscope.

As a result, it was confirmed that Pellino 1 is normally located at the p13.3 locus of chromosome 2 together with the control body located on chromosome 2 in five cell lines performed, and no chromosomal structural abnormalities were observed ( 1).

Example  4: Pellino  Immunohistochemical Staining Analysis of Patients with Diffuse Large Cell B Cell Lymphoma Using Antibodies

Two tissue microarry (TMA) blocks were prepared for each case of diffuse large B cell lymphoma. The TMA block was cut into 4 μm thickness, subjected to deparaffinization, and then stepped into ethyl alcohol. Tissue blocks were immersed in EDTA buffer at pH 9.0, heat treated at 95 ° C. for 18 minutes, cooled at room temperature, and then cooled to 3%. Soak for 5 minutes in hydrogen peroxide. Pellino 1 antibody (rabbit monoclonal, Proteintech, Chicago, IL, USA) was diluted at a ratio of 1:50 and reacted at room temperature for 30 minutes, followed by reaction using ENVISION Flex and rabbit kit (DakoCytomation, Glostrup, Denmark). Positive cases were found in which the nuclei of 5% or more lymphoma cells stained brown.

As a result, in the tissues of patients with diffuse large B-cell lymphoma, Pellino 1 was strongly stained brown in the nucleus, and was significantly different from the control group that did not express Pellino 1 (FIG. 2).

Example  5: Pellino 1 Expression Division  Correlation of Clinical Pathologic Features in Patients with B Cell Lymphoma

From February 2003 to January 2008, 108 patients were diagnosed with diffuse large B-cell lymphoma at Seoul National University Hospital. The diagnosis of malignant lymphoma was in accordance with the WHO classification published in 2001, and the patient's gender, age at diagnosis, Ann-Arbor stage, international performance index (IPI) scores, and follow-up were referred to by the results read by two blood pathologists. Observation period, mortality, and EBV in situ hybridization were examined. The correlation between the clinical pathological characteristics and the results of immunohistochemical staining of Pellino 1 (FIG. 3) is shown in Table 2 below.

As a result, positive Pellino 1 expression was identified in 77 cases out of 108 cases, and only 31 cases were judged negative for Pellino 1 expression. In particular, the more severe the B-cell lymphoma in Ann-Arbor stage and IPI, which classifies the stage and malignancy of B-cell lymphoma, the more Pellino 1 expression-positive cases increased by about 30%. This indicates that Pellino 1 expression is higher as diffuse large B-cell lymphoma worsens (Table 2).

Example  6: Pellino 1 Expression Division Diffuse large cytoplasm  Prognostic Correlation of Patients with B Cell Lymphoma

Statistical analysis was performed using SPSS 17.0 (SPSS, Chicago, IL, USA) software. Correlations between the clinicopathologic factors and Pellino 1 expression were categorized and analyzed using chi-square test and Fisher's exact test. Survival analysis was performed using Kaplan-Meier analysis. In the bilateral test, the p- value less than 0.05 was determined to be statistically significant.

Statistical analysis showed that the expression of Pellino 1 is closely related to the poor prognosis of patients with diffuse large B-cell lymphoma. In particular, in the case of Pellino 1-expression negative patients, the cumulative survival rate remained unchanged until 60 months, while in the case of Pellino 1-expression-positive patients, the survival rate was reduced by about 40% (Fig. 3). .

Example  7: Real time polymerase chain reaction Real - time PCR Using mouse Pellino 1 mRNA  Expression comparison

Real-time polymerase chain reaction was performed to compare mRNA levels of Pellino 1 in each mouse tissue. The PCR reaction solution was added with 25 nM and 10 ng cDNA of 7.5 μl 2 × SYBRGreen PCR Master Mix (Applied Biosystems), Pellino 1, and GAPDH forward and reverse primers, respectively. Abi PRISM 7000 (AppliedBiosystems) using a device for 50 ℃ 2 minutes, 95 ℃ 10 minutes reaction, 95 ℃ 15 seconds 60 ℃ 1 minute two steps of 40 cycles amplified reaction and measure the threshold cycle value 2 ^ddCT method Was quantified. Comparison of mRNA expression of Pellino 1 in various tissues showed high mRNA expression in tissues with many immune cells such as trachea, lymph node and thymus, especially CD8 T cells and CD4 T cells. And the expression of Pellino 1 mRNA in immune cells such as LPS (Lipopolysaccharide) -treated macrophages was remarkably high. This indicates the association of Pellino 1 with immune cells. This result is the result of merging the results of the research team and the data of the BioGPS site ( http://biogps.gnf.org ) (FIG. 4).

<Pellino 1>

Forward primer TGTAGTAACTGACACGGTTCCT (SEQ ID NO: 1)

Reverse primer TCCATCTGATGTCTTCCATTTGG (SEQ ID NO: 2)

<GAPDH>

Forward primer GGCATGGACTGTGGTCATGAG (SEQ ID NO: 3)

Reverse primer TGCACCACCAACTGCTTAGC (SEQ ID NO: 4)

<110> SUNGKYUNKWAN UNIVERSITY Foundation for Corporate Collaboration <120> Pellino 1 as a marker for the diagnosis or prognosis of lymphoma <130> PA100141KR <160> 4 <170> KopatentIn 1.71 <210> 1 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for Pellino 1 <400> 1 tgtagtaact gacacggttc ct 22 <210> 2 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for Pellino 1 <400> 2 tccatctgat gtcttccatt tgg 23 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for GAPDH <400> 3 ggcatggact gtggtcatga g 21 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for GAPDH <400> 4 tgcaccacca actgcttagc 20

Claims (13)

Pellino 1 (Genbank ID: 57162) A composition for the diagnosis or prognosis of lymphoma, comprising a gene measuring the mRNA or protein level thereof.
The composition of claim 1, wherein the lymphoma is Hodgkin's lymphoma, non-Hodgkin's lymphoma or B-cell lymphoma.
The composition of claim 1, wherein the agent for measuring the expression level of mRNA of the gene comprises an antisense oligonucleotide, primer pair or probe that Pellino 1 specifically binds to the gene.
The composition of claim 1, wherein the agent for measuring the expression level of the protein comprises an antibody specific for a protein of Pellino 1.
Kit for diagnosis or prognosis of lymphoma comprising the composition of any one of claims 1 to 4.
The kit of claim 5, wherein the kit is an RT-PCR kit, microarray chip kit, DNA kit or protein chip kit.
Measuring mRNA from a biological sample of suspected lymphoma using primers that specifically bind to the Pellino 1 gene; And
Comparing the increase of the mRNA level with the mRNA level of the normal control sample method of providing information for the diagnosis or prognosis of lymphoma.
Contacting an antibody specific for a Pellino 1 protein with a biological sample of a suspected lymphoma to confirm protein levels by antigen-antibody complex formation; And
Comparing the increase in the amount of protein formation with the protein level of the normal control sample for providing information for the diagnosis or prognosis of lymphoma.
The method of claim 7 or 8, wherein the sample is any one or more samples selected from the group consisting of whole blood, serum, plasma, saliva, urine, sputum, lymph, and cells isolated from an individual.
The method of claim 7 or 8, wherein the lymphoma is Hodgkin's lymphoma, non-Hodgkin's lymphoma or B-cell lymphoma.
The method of claim 8, wherein the antigen-antibody response levels are compared by Western blotting, ELISA, radioimmunoassay, radioimmunoassay, oukteroni immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, Complement complement assay, FACS or protein chip.
(a) treating lymphoma cells with a candidate material for treating lymphoma;
(b) measuring the expression level of the pellino 1 gene or the expression level of the protein encoded by the candidate substance-treated cells; And
(c) comparing the expression level of the pellino 1 gene or the expression level of the protein encoded by the gene with a control.
The method of claim 12, wherein the lymphoma is Hodgkin's lymphoma, non-Hodgkin's lymphoma or B-cell lymphoma.

Images